[Translation] A randomized, open-label, single-dose, fasting and fed, two-formulation, two-sequence, two-period crossover bioequivalence study of montelukast sodium granules in healthy adult Chinese subjects
观察在空腹和餐后状态下单次口服受试制剂孟鲁司特钠颗粒T(规格:0.5g:4mg,以孟鲁司特计,亚宝药业四川制药有限公司生产)与参比制剂孟鲁司特钠颗粒R(商品名:顺尔宁®,规格:0.5g:4mg,以孟鲁司特计,Merck Sharp & Dohme Corp生产)在中国成年健康受试者体内的药代动力学特征,初步评估空腹与餐后状态下分别口服两种制剂后,T和R之间的生物等效性及个体内变异度。观察在空腹和餐后状态下单次口服受试制剂和参比制剂0.5g:4mg在中国成年健康受试者中的安全性。
[Translation] The pharmacokinetic characteristics of the test preparation, montelukast sodium granules T (specification: 0.5g:4mg, calculated as montelukast, produced by Yabao Pharmaceutical Sichuan Pharmaceutical Co., Ltd.) and the reference preparation, montelukast sodium granules R (trade name: Singulair®, specification: 0.5g:4mg, calculated as montelukast, produced by Merck Sharp & Dohme Corp) were observed in healthy adult Chinese subjects after a single oral administration in the fasting and fed state, and the bioequivalence and intra-individual variability between T and R were preliminarily evaluated after oral administration of the two preparations in the fasting and fed state, respectively. The safety of the test preparation and the reference preparation 0.5g:4mg in healthy adult Chinese subjects after a single oral administration in the fasting and fed state was observed.